Appili Therapeutics Inc is seeing a significant rise in its stock price, catching the attention of Canadian investors.
Today, Appili Therapeutics Inc (APLI.TO) has seen its stock price jump by 50%. This sharp increase is drawing interest from investors eager to take advantage of the momentum surrounding this small-cap biotechnology firm.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
266.4%
Annualized
90-Day Vol
252.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.03 |
| 90 trading days | C$0.01 | C$0.00 – C$0.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the potential of Appili Therapeutics as it develops its infectious disease programs, especially following its recent funding successes.
APLI.TO Surges by 50% in One Day
With a real-time close of CA$0.01, today’s performance marks a notable turnaround for Appili Therapeutics.
Bull case
The company has made significant strides in securing funding for its projects, including a US$40 million award from NIAID. This funding boosts its credibility and operational capacity, indicating a promising future.
Bear case
Despite today's surge, the stock remains highly speculative. It currently has no profit margin and a market cap of just over CA$1.3 million, making it susceptible to market fluctuations.
Stock Performance Overview
Advertisement
Appili Therapeutics Inc is experiencing a notable rise in its stock price today, reflecting a 50% increase. This surge likely stems from investor optimism about the company's ongoing projects and recent funding achievements. With a market cap of CA$1.3 million, the stock's low price point may attract speculative investors.
Funding and Future Prospects
The recent US$40 million award from NIAID highlights Appili's potential in the infectious disease sector, positioning it for growth. Investors should keep an eye on the company's developments and funding announcements, as these could further influence stock performance. For more detailed insights, check out the Appili Therapeutics stock page.
Market Sentiment and Risks
While today’s stock increase paints a positive picture, it’s important to consider the risks associated with investing in small-cap biotechnology firms like Appili. The lack of profitability and the company’s speculative nature mean that investors should proceed with caution. For ongoing updates, visit the Wealth Awesome stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
